Regeneron Pharmaceuticals Inc NASDAQ NMS - GLOBAL MARKET:REGN
The leadership team, board of directors, and 10% beneficial owners of Regeneron Pharmaceuticals Inc, reconstructed from SEC insider filings and proxy statements.
Other Reporting Persons
Other Section-16 reporting persons associated with the issuer.
BROWN MICHAEL S
—5,000 sharesFenimore Christopher R.
—1,897 sharesLAROSA JOSEPH J
—3,402 sharesMcCourt Marion
—197 sharesMURPHY ANDREW J
—4,375 sharesPitofsky Jason
—179 sharesSCHLEIFER LEONARD S
—39,985 sharesSING GEORGE L
—400 sharesVan Plew Daniel P
—1,129 sharesYANCOPOULOS GEORGE
—180,000 shares
Recent Form 4 Activity last 90 days
No insider transactions in the last 90 days.
View all insider tradesMethodology
Officers and directors are derived from SEC Forms 3, 4, and 5 filed by reporting persons for this issuer. The roster reflects the most recent disclosed relationship per individual. Officer titles use the issuer-supplied designation from the relationship record.
Independence flags and board committee assignments are sourced from the most recent DEF 14A proxy statement when available. For executive compensation context — base salary, equity grants, performance metrics — refer to the Summary Compensation Table in the issuer's annual proxy.
Cross-references: where a reporting person is matched to a consolidated people profile (same CIK across multiple issuers), the person link routes to the unified profile page so you can see every board seat and officer role in one place.